SIG
MLTX icon

Senator Investment Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Senator Investment Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-155,000
Closed -$9.36M – 82
2023
Q4 		$9.36M Buy
+155,000
New +$7.99M 0.4% 53

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Senator Investment Group's MLTX Position: Q1 2024 in Review

Senator Investment Group sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2024, closing a stake of 155,000 shares — an estimated $9.36M sold.

Senator Investment Group first reported a position in MLTX in Q4 2023 and held it in 1 quarter. The position peaked at $9.36M in Q4 2023. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • Senator Investment Group reported no remaining MoonLake Immunotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Senator Investment Group sold 155,000 MoonLake Immunotherapeutics shares in Q1 2024, an estimated $9.36M.
  • Senator Investment Group first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 1 quarter.
  • Senator Investment Group's MoonLake Immunotherapeutics position peaked at $9.36M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Senator Investment Group's 13F filing for Q1 2024, filed 14 May 2024.